Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. [electronic resource]
Producer: 20120629Description: 1691-6 p. digitalISSN:- 1791-2423
- Animals
- Antineoplastic Agents -- pharmacology
- Blotting, Western
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Down-Regulation
- Drug Resistance, Neoplasm
- Female
- Humans
- Indoles -- pharmacology
- Lymphocytes, Tumor-Infiltrating -- drug effects
- Mice
- Mice, Inbred C3H
- Mice, Nude
- Mitogen-Activated Protein Kinase 1 -- antagonists & inhibitors
- Mitogen-Activated Protein Kinase 3 -- antagonists & inhibitors
- Phosphorylation
- Protein Kinase Inhibitors -- pharmacology
- Pyrroles -- pharmacology
- Signal Transduction -- drug effects
- Sunitinib
- T-Lymphocytes, Cytotoxic -- drug effects
- T-Lymphocytes, Regulatory -- drug effects
- Time Factors
- Tumor Burden -- drug effects
- Urinary Bladder Neoplasms -- drug therapy
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.